Shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) shot up 3.3% during mid-day trading on Wednesday . The stock traded as high as $32.54 and last traded at $32.45, with a volume of 208,968 shares trading hands. The stock had previously closed at $31.42.

Several research firms recently issued reports on ZLTQ. Piper Jaffray Cos. reissued an “overweight” rating and issued a $40.00 price target on shares of Zeltiq Aesthetics in a research report on Monday, May 2nd. Zacks Investment Research downgraded shares of Zeltiq Aesthetics from a “hold” rating to a “sell” rating in a report on Thursday, July 14th. Brean Capital reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a report on Thursday, April 28th. TheStreet downgraded shares of Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a report on Friday, June 10th. Finally, Goldman Sachs Group Inc. lifted their price objective on shares of Zeltiq Aesthetics from $35.00 to $37.00 in a report on Friday, April 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zeltiq Aesthetics currently has a consensus rating of “Buy” and an average price target of $36.63.

The company has a market cap of $1.28 billion and a P/E ratio of 38.93. The firm has a 50-day moving average price of $28.84 and a 200 day moving average price of $26.34.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its earnings results on Tuesday, May 10th. The company reported ($0.25) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.25). The company earned $64.50 million during the quarter, compared to analysts’ expectations of $61.80 million. During the same quarter last year, the firm posted ($0.06) EPS. Zeltiq Aesthetics’s revenue for the quarter was up 25.0% compared to the same quarter last year. On average, analysts predict that Zeltiq Aesthetics Inc. will post $0.01 earnings per share for the current fiscal year.

In related news, CEO Mark J. Foley sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $31.21, for a total transaction of $312,100.00. Following the completion of the transaction, the chief executive officer now owns 325,940 shares in the company, valued at approximately $10,172,587.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Keith J. Sullivan sold 8,000 shares of the business’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $30.02, for a total value of $240,160.00. Following the transaction, the insider now owns 77,922 shares of the company’s stock, valued at approximately $2,339,218.44. The disclosure for this sale can be found here.

A number of institutional investors have bought and sold shares of the stock. State of Tennessee Treasury Department acquired a new position in Zeltiq Aesthetics during the fourth quarter worth about $2,853,000. Trexquant Investment LP acquired a new position in Zeltiq Aesthetics during the fourth quarter worth about $1,640,000. Wells Fargo & Company MN boosted its position in Zeltiq Aesthetics by 765.2% in the fourth quarter. Wells Fargo & Company MN now owns 404,376 shares of the company’s stock worth $11,537,000 after buying an additional 357,636 shares during the last quarter. New York State Common Retirement Fund boosted its position in Zeltiq Aesthetics by 4.3% in the fourth quarter. New York State Common Retirement Fund now owns 41,532 shares of the company’s stock worth $1,185,000 after buying an additional 1,700 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Zeltiq Aesthetics by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 59,726 shares of the company’s stock worth $1,704,000 after buying an additional 984 shares during the last quarter.

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.